Corbus Pharmaceuticals Holdings, Inc.
CRBP Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$4.05
KIRA · Stoqly’s AI analyst, in plain words
- Corbus Pharmaceuticals Holdings, Inc. lost $78.5M in fiscal 2025.
- Free cash flow was −$64.5M in fiscal 2025, — of revenue.
Market cap
$78.6M
P/E
—
Revenue
—
Net income
−$78.5M
Free cash flow
−$64.5M
Operating margin
—
Corbus Pharmaceuticals Holdings, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$78.5M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Corbus Pharmaceuticals Holdings, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 9, 2026
- Legal name
- Corbus Pharmaceuticals Holdings, Inc.
- CIK
- 0001595097
Corbus Pharmaceuticals Holdings, Inc. · CRBP
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.9M | $0.0M | −$2.9M | — | — |
| Revenue growth | −77.6% | −100.0% | — | — | — |
| Net interest income | −$1.8M | −$2.1M | −$2.9M | — | — |
| Operating margin | −6,350.1% | — | 1,541.7% | — | — |
| Net income | −$45.6M | −$42.3M | −$44.6M | −$40.2M | −$78.5M |
| Net margin | −5,176.4% | — | 1,525.4% | — | — |
| Diluted EPS | −$11.15 | −$10.15 | −$10.31 | −$3.68 | −$5.90 |
| Cash | |||||
| Cash from operations | −$48.2M | −$37.5M | −$36.1M | −$41.8M | −$64.5M |
| Capital expenditure | $0.1M | $0.0M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$48.2M | −$37.6M | −$36.1M | −$41.8M | −$64.5M |
| FCF margin | −5,471.0% | — | 1,234.6% | — | — |
| Share count change | −94.8% | 1.9% | 3.8% | 152.2% | 22.0% |
| Debt and strength | |||||
| Cash and short-term investments | $97.6M | $59.2M | $20.9M | $149M | $163M |
| Debt incl. finance leases | $21.2M | $21.6M | $17.9M | — | — |
| Shareholders' equity | $69.1M | $33.0M | −$6.9M | $142M | $148M |
| Current ratio | 5.9x | 4.8x | 0.7x | 12.9x | 8.1x |
| Interest coverage | −20.7x | −12.9x | −11.7x | −26.0x | — |
| Returns and quality | |||||
| Return on equity | −79.8% | −83.0% | −342.0% | −59.3% | −54.2% |
| Return on tangible equity | −66.0% | −128.4% | — | −28.2% | −53.2% |
| Piotroski F-score | 4 | 1 | 1 | — | — |
| Altman Z'' | −7.1 | −17.6 | −63.2 | 5.0 | −1.0 |
Insiders bought, 12 months
$0.1M
1 insider
Insiders sold, 12 months
$1.0M
9 insiders
Of sales under plans
54%
$0.5M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Corbus Pharmaceuticals Holdings, Inc. · CRBP
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $4.05 a share, the company is worth $78.6M.
Source: SEC EDGAR XBRL filings (CIK 0001595097). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.